← Leaderboards
Hui-Ming Chang
University Of Missouri-Columbia
$3,417,937
Attributed
$3,417,937
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $763.8K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,417,937 · 1
By mechanism
R01$3,417,937 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Shon R Pulley$166,849
- Michael Harmata$933,737
- Guido Lastra$838,510
Others in their field
Other Emerging Leaders on “Cost Effective”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- John Damon Chodera · Sloan-Kettering Inst Can Research$36,078,498
- Karen Martier · Westat, Inc.$35,207,008
- Gary Fanger · Rise Therapeutics, Llc$21,006,928
- Chani Eduard · Precision Bioservices, Inc.$19,909,203
Research focus
Cost EffectiveDexrazoxaneAdultAnimal ModelBindingAnthracyclineAtpase DomainBreast Cancer PatientBreast Cancer TreatmentCancer CellCancer PatientCancer SurvivorCancer TherapyBiological MarkersBloodCardiac MyocytesCardioprotectionCardiotoxicityCell DeathCell DivisionChemotherapyChemotherapy-Oncologic ProcedureChildhood LeukemiaDisease-Free Survival
Grant awards (5)
Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane$489,570
R01 · FY2024 · HL · contact PI
Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane$710,737
R01 · FY2023 · HL · contact PI
Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane$726,166
R01 · FY2022 · HL · contact PI
Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane$727,686
R01 · FY2021 · HL · contact PI
Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane$763,778
R01 · FY2020 · HL · contact PI